65 completed, 27 active not recruiting, 23 recruiting, 14 terminated. 74 Phase 2, 30 Phase 3, 27 Phase 1, 6 Not applicable, 2 Early Phase 1.
Follow Anti-VEGF: new trials by email Literature Review of Anti-VEGF trials Research Report on Anti-VEGF
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection - Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 87 | 2026-09-24 | 2026-10-20 |
| A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema Oral BGE-102, Oral Placebo Matching BGE-102, Anti-VEGF - Diabetic Macular Edema (DME) | Phase 2 | Recruiting | BioAge Labs, Inc. | 180 | 2026-08-21 | 2026-09-10 |
| Longitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF Agents Anti-Vascular Endothelial Growth Factor - Diabetic Retinal Disease | Phase 4 | Recruiting | Jaeb Center for Health Research | 100 | 2026-07-31 | 2026-10-23 |
| Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody - Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 535 | 2026-05-01 | 2026-10-16 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer Bevacizumab, Biospecimen Collection, Carboplatin - Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 255 | 2026-01-27 | 2026-10-23 |
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial Chemotherapy, Computed Tomography, Internet-Based Intervention - Glioma, Recurrent Glioma | Not applicable | Recruiting | Mayo Clinic | 202 | 2025-09-12 | 2026-08-10 |
| External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer Bevacizumab, Biospecimen Collection, Brachytherapy - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 35 | 2025-07-29 | 2026-08-12 |
| BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases Anti-VEGF, Immunotherapy, Local Therapy - Hepatocellular Carcinoma, Portal Vein Tumor Thrombus | Phase 2 | Recruiting | Shandong Cancer Hospital and Institute | 54 | 2025-07-25 | 2026-10-15 |
| Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 24 | 2025-06-23 | 2026-09-09 |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 3 | Recruiting | NRG Oncology | 880 | 2025-03-12 | 2026-08-07 |
| Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma Bevacizumab, Biospecimen Collection, Computed Tomography - Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 134 | 2024-10-02 | 2024-11-19 |
| Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC Anti-PD-1/PD-L1 antibodies, Anti-VEGF - Hepatocellular Carcinoma | Recruiting | Shanghai Zhongshan Hospital | 50 | 2024-08-01 | 2025-12-15 | |
| Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial Bevacizumab, Capecitabine, Cetuximab - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 408 | 2024-04-10 | 2026-09-24 |
| Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab - Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 80 | 2024-03-12 | 2026-08-14 |
| Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS], Ultra-wide Fluorescein Angiography - Retinal Vein Occlusion, Macular Edema | Unknown | Renmin Hospital of Wuhan University | 60 | 2023-10-09 | 2023-10-18 | |
| FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer Balstilimab, Bevacizumab, Biospecimen Collection - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 20 | 2023-05-03 | 2026-09-01 |
| APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Bevacizumab, Biopsy, Biospecimen Collection - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 60 | 2023-04-27 | 2026-03-23 |
Showing 20 of 138. Sign in to see all of them.
Ovarian Neoplasms (23) · Fallopian Tube Neoplasms (19) · Colorectal Neoplasms (13) · Glioblastoma (9) · Breast Neoplasms (8) · Carcinoma, Renal Cell (8) · Brenner Tumor (7) · Carcinoma, Non-Small-Cell Lung (7) · Lung Neoplasms (7) · Brain Neoplasms (6) · Carcinoma, Hepatocellular (6) · Colonic Neoplasms (6) · Melanoma (6) · Rectal Neoplasms (5) · Gliosarcoma (4)
National Cancer Institute (NCI) (67) · M.D. Anderson Cancer Center (14) · Academic and Community Cancer Research United (5) · Mayo Clinic (5) · Roswell Park Cancer Institute (5) · City of Hope Medical Center (4) · NRG Oncology (2) · Northwestern University (2) · OHSU Knight Cancer Institute (2) · Wenzhou Medical University (2) · Allergan (1) · Anne Noonan (1) · BioAge Labs, Inc. (1) · Clearside Biomedical, Inc. (1) · ECOG-ACRIN Cancer Research Group (1)
United States (122) · Canada (17) · Puerto Rico (8) · China (6) · Australia (5) · Japan (4) · Peru (4) · South Africa (4) · South Korea (3) · New Zealand (2) · Germany (1) · Hong Kong (1) · Hungary (1) · Ireland (1) · Israel (1)
Emese Zsiros (3) · Hope S Rugo (2) · Mark Gilbert (2) · Yong Wei, M.D (2) · Aaron S Mansfield (1) · Aarti Bhatia (1) · Adam S Levy (1) · Agustin Garcia (1) · Ahmed O Kaseb (1) · Akila Viswanathan (1) · Al B Benson (1) · Alice P Chen (1) · Amanda N Fader (1) · Andras Papp, MD, PhD (1) · Anil K. Sood, MD (1)
PMID 37185961, PMID 34616010, PMID 21941283, PMID 21997132, PMID 22178121, PMID 22204724, PMID 23219660, PMID 23233715, PMID 23620404, PMID 24047116, PMID 24552317, PMID 24552320, PMID 24817603, PMID 25092775, PMID 25318437, PMID 25488966, PMID 25638326, PMID 25713428, PMID 25847373, PMID 25926352, PMID 26056183, PMID 26077237, PMID 26487588, PMID 26576593, PMID 26933849, PMID 27138575, PMID 27217446, PMID 28006055, PMID 28384065, PMID 28438473, PMID 28620884, PMID 28646344, PMID 28756902, PMID 29129443, PMID 29169877, PMID 29550184, PMID 29789969, PMID 30040523, PMID 30054636, PMID 31002578, PMID 31216226, PMID 31268130, PMID 31276981, PMID 31393548, PMID 31513481, PMID 31618129, PMID 31708167, PMID 31722153, PMID 31790344, PMID 31811950
U10CA180868 (21), U10CA027469 (13), U10CA180820 (11), U10CA180821 (8), P30CA015083 (7), U10CA021115 (7), P30CA033572 (6), U10CA021661 (6), U10CA031946 (6), U10CA032102 (4), U10CA180888 (4), N01CM00038 (3), P30CA060553 (3), U10CA098543 (3), N01CM00039 (2)